Summary
A possible antimanic property of the GABA-ergic anticonvulsant valproate was examined by use of a double-blind placebo-controlled ABA design in 5 acutely ill manic patients. In 4 cases a marked improvement was observed after valproate medication whereas one patient showed no response. Seven further patients with frequently recurrent episodes of a manic or maniform schizoaffective psychosis, irresponsive to lithium prophylaxis, were chronically treated with valproate in combination with low doses of lithium (one case only with valproate). Over an observation period of 1 1/2–3 years none of the patients exhibited a relapse. It is proposed that, in general, GABA-ergic anticonvulsants possess antimanic properties and that the specific antimanic effect of lithium is due to a GABA-ergic mode of action. The possible role of GABA-systems in affective disorders and in organic types of psychoses (e.g., porphyria-psychosis, delirium tremens) is discussed on the basis of pharmacopsychiatric considerations.
Zusammenfassung
Unter Verwendung eines doppel-blinden ABA-Designs mit Placebo-Kontrolle wurde bei 5 Patienten mit akuter Manie eine mögliche antimanische Wirkung des GABA-ergen Anticonvulsivums Valproat untersucht. Bei 4 Patienten wurde eine deutliche Besserung beobachtet, während ein Patient auf Valproat nicht reagierte. Bei 7 weiteren Patienten mit häufig wiederkehrenden Phasen einer manischen oder maniformen schizoaffektiven Psychose, die auf die Lithium-Prophylaxe nicht ansprachen, wurde eine Dauerbehandlung mit Valproat in Kombination mit kleinen Lithium-Dosen durchgeführt. (In einem Fall wurde nur Valproat, ohne Lithium, gegeben.) Im Verlauf einer Beobachtungsphase von 1 1/2–3 Jahren wurde bei keinem dieser Patienten ein Rückfall beobachtet. Es wird die Hypothese vorgeschlagen, daß grundsätzlich GABA-erge Anticonvulsiva antimanische Eigenschaften aufweisen und daß auch der spezifische antimanische Effekt von Lithium auf einer GABA-ergen Wirkungskomponente beruht. Eine mögliche pathophysiologische Bedeutung zentraler GABA-Systeme bei affektiven und organischen Psychosen (z.B. Porphyrie, Delirium tremens) wird auf der Basis pharmakopsychiatrischer Überlegungen diskutiert.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aldenhoff JB, Lux HD (1979) The influence of lithiumchlorid on ionic conductance of a bursting pacemaker neuron of helix pomatia. Pflügers Arch ges Physiol 379:R117
Anlezark G, Horton RW, Meldrum BS, Sawaya MCB (1976) Anticonvulsant action of ethanolamine-O-sulphate and di-n-propylacetate and the metabolism of γ-aminobutyric acid (GABA) in mice with audiogenic seizures. Biochem. Pharmacol. 25:414–417
Atsmon A, Blum J (1970) Treatment of acute porphyria variegata with propranolol. Lancet I, 196–197
Atsmon A, Blum J, Steiner M, Latz A, Wijsenbeek H (1972) Further studies with propranolol in psychotic patients. Psychopharmacologia 27:249–254
Beckmann H, Frische M, Rüther E, Zimmer R (1977) Baclofen (para-chlorphenyl-GABA) in schizophrenia. Pharmakopsychiat 10:26–31
Beckmann H, Haas S (1980, in press) High dose diazepam in schizophrenia. Psychopharmacology
Bernasconi R, Martin P (1979) Effects of antiepileptic drugs on the GABA turnover rate. Arch Pharmacol 307:251
Brassuer R (1978) Depakine bei der Behandlung des chronischen Alkoholismus. Therapiewoche 28:9981–9984
Brennan MJW (1980, in press) GABA autoreceptors: structure-activity relationship for agonists. In: Di Chiara G (ed) GABA and benzodiazepines receptors and glutamate as a neurotransmitter. Raven Press, New York
Brennan MJW, Cantrill RC (1979) The effect of delta-aminolaevulinic acid on the uptake and efflux of [3H] GABA in rat brain synaptosomes. J Neurochem 32:1781–1786
Cooper TB, Gershon S, Kline NS, Schou M (eds) (1979) Lithium. Controversis and unresolved issues. Excerpta Medica, Amsterdam Oxford Princeton
Costa E, Guidotti A, Mao CC, Suria A (1975) New concepts on the mechanism of action of benzodiazepines. Life Sci 17:167–186
Curtis DR, Game CJA, Johnston GAR, McCulloch RM (1974) Central effects of beta (p-chlorophenyl) aminobutyric acid. Brain Res 70:493–499
Davies J, Watkins JC (1974) The action of betaphenyl-GABA derivatives on neurones of the cat cerebral cortex. Brain Res 70:501–505
Deisz RA, Lux HD (1977) Diphenylhydantoin prolongs postsynaptic inhibition and iontophoretic GABA action in the crayfish stretch receptor. Neurosci Lett 5:199–203
Delini-Stula A, Meier M (1976) Inhibitory effects of propranolol and oxprenolol on excitation induced by a MAO inhibitor and reserpine in the mouse. Neuropharmacology 15:383–388
Delini-Stula A, Vassout A (1978) Modulatory effects of baclofen muscimol and GABA on inter-specific aggressive behaviour in the rat. Neuropharmacology 17:1063–1065
Emrich HM, Cording C, Pirée S, Kölling A, v Zerssen D, Herz A (1977) Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiat 10:265–270
Emrich HM, v Zerssen D, Möller, H-J, Kissling W, Cording C, Schietsch HJ, Riedel E (1979) Action of propranolol in mania: comparison of effects of the d- and the l-stereoisomer. Pharmakopsychiat 12:295–304
Faigle JW, Keberle H (1972) Metabolismus und Pharmakokinetik von Lioresal. In: Birkmayer W (Hrsg) Aspekte der Muskelspastik. Huber, Bern Stuttgart Wien, S 94–100
Frederiksen PK (1975) Baclofen in the treatment of schizophrenia. Lancet I, 702
Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton D, Antonias JI, Schimschock JC (1979) Reye-like syndrome associated with valproic acid therapy. J Pediatr 95:142–144
Gündürewa M, Beckmann H, Zimmer R, Rüther E (1980, in press) Wirkung von Valproinsäure auf schizophrene Symptome. Arzneim-Forsch/Drug Res
Harvey PKP, Brandford HF, Davison AN (1975) The inhibitory effect of sodium n-dipropylacetate on the degradative enzymes of the GABA shunt. FEBS Letters 52:251–254
Hillbom ME (1975) The prevention of ethanol withdrawal in rats by dipropylacetat. Neuropharmacology 14:755–761
Johnson FN (ed) (1980) Handbook of lithium therapy. MTP Press, Lancaster
Kammen DP van (1977) γ-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. Am J Psychiatr 134:138–143
Kelly J, Alheid GF, Newberg A, Grossmann SP (1977) GABA stimulation and blockade in the hypothalamus and midbrain: effects on feeding and locomotor activity. Pharmacol Biochem Behav 7:537–541
Klotz U (1977) Pharmacokinetic studies with valproic acid in man. Arzneim-Forsch/Drug Res 27:1085–1088
Köhler G-K (1975) Epileptische Psychosen — Klassifikationsversuche und EEG-Verlaufsbeobachtungen. Fortschr Neurol Psychiat 3:99
Krogsgaard-Larsen P, Scheel-Krüger J, Kofod H (eds) (1979) GABA-neurotransmitters. Munksgaard, Copenhagen
Kubanek JL, Rowell RC (1946) The use of dilantin in the treatment of psychotic patients unresponsive to other treatment. Dis Nerv Syst 7:1–4
Lambert P-A, Borselli S, Midenet J, Baudrand C, Marcou G, Bouchardy M (1968) L'action favorable du Dépamide sur l'évolution à long terme des psychoses maniaco-depressives. Compte rendu du Congrès de Psychiatrie et de Neurologie de langue française, 66 session, Clermont-Ferrand, 16–21 septembre 1968, pp 489–493
Lambert P-A, Borselli S, Marcou G, Bouchardy M, Cabrol C (1971) Action thymorégulatrice à long terme du Dépamide dans la psychose maniaco-dépressive. Ann Med Psychol (Paris) 2:442–447
Lambert P-A, Carraz G, Borselli S, Carrel S (1966) Action neuro-psychotrope d'un nouvel anti-épileptique: le Dépamide. Ann Med Psychol (Paris) 1:707–710
Lambert P-A, Carraz G, Borselli S, Bouchardy M (1975) Le dipropylacétamide dans le traitement de la psychose maniaco-dépressive. L'Encéphale I:25–31
Lorr M, Klett CJ, McNair DM, Lasky JJ (1962) Impatient multidimensional psychiatric scale. Consulting Psychologists Press, Palo Alto/California
Löscher W, Esenwein H (1978) Gaschromatographischer Nachweis von Valproat. Arzneim-Forsch/Drug Res 28:782–785
Maggi A, Enna SJ (1980) Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment. J Neurochem 34:888–892
Mandel P, Mack G, Kempf E (1979) Molecular basis of some models of aggressive behavior. In: Sandler M (ed) Psychopharmacology of aggression. Raven Press, New York, pp 95–110
Möller H-J, Zerssen D v, Emrich HM, Kissling W, Cording C, Schietsch HJ, Riedel E (1979) Action of d-propranolol in manic psychoses. Arch Psychiat Nervenkr 227:301–317
Murphy DL, Beigel A, Weinbartner H, Bunney WE (1974) The quantitation of manic behavior. In: Pichot P (ed) Psychological measurements in psychopharmacology. Karger, Basel, pp 203–220
Nicoll R (1978) Selective actions of barbiturates on synaptic transmission. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: A generation of progress. Raven Press, New York, pp 1337–1348
Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M (1979) Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology 66:211–217
Okuma T, Kishimoto A, Inone K (1973) Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychoses. A preliminary report. Folia Psychiat Neurol Jpn 27:283–297
Pinder RM, Brogden RN, Speight TM, Avery GS (1977) Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 13:81–123
Rackensperger W, Fritsch W, Schwarz D, Stutte KH, Zerssen D v (1976) Wirkung des Beta-Rezeptoren-Blockers Propranolol auf Manien. Arch Psychiat Nervenkr 222:223–243
Rackensperger W, Gaupp R, Mattke DJ, Schwarz D, Stutte KH (1974) Behandlung von akuten schizophrenen Psychosen mit Beta-Rezeptoren-Blockern. Arch Psychiat Nervenkr 219:29–36
Roberts E (1972) An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neurosci Res Prog Bull 10:468–482
Schwarz D, Mertin J (1973) Die Anwendung von Propranolol bei der akuten intermittierenden Porphyrie. Nervenarzt 44:648–651
Stevens J, Wilson K, Foote W (1974) GABA blockade, dopamide and schizophrenia: experimental studies in the cat. Psychopharmacologia (Berl) 39:105–119
Suchy FJ, Balistreri WF, Buchino JJ, Sondheimer JM, Bates SR, Kearns GL, Stull JD, Bove KE (1979) Acute hepatic failure associated with the use of sodium valproate. N Engl J Med 300:962–966
Supavilai P, Karobath M (1980) Ethanol and other CNS depressants decrease GABA-synthesis in mouse cerebral cortex and cerebellum in vivo. Life Sci 27:1035–1040
Tapia R (1974) The role of γ-aminobutyric acid metabolism in the regulation of central excitability. In: Myers RD, Drucker-Colin RR (eds) Neurohumoral coding of brain function. Plenum Press, New York London, pp 3–26
Vassout A, Delini-Stula A (1977) Effects de β-bloquers (propranolol et oxprénolol) et du diazépam sur différents modéles d'agressivité chez le rat. J Pharmacol (Paris) 8:5–14
Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ (1978) Effect of valproic acid on hepatic function. Neurology 28:961–964
Wu J-Y, Roberts E (1974) Properties of brain L-glutamate decarboxylase: inhibition studies. J Neurochem 23:759–767
Zerssen D v (1976) Beta-adrenergic blocking agents in the treatment of psychoses. A report on 17 cases. In: Carlsson C, Engel J, Hansson L (eds) Neuro-psychiatric effects of adrenergic beta-receptor blocking agents. Urban & Schwarzenberg, München Berlin Wien, pp 105–114
Zerssen D v, Cording C (1978) The measurement of change in endogenous affective disorders. Arch Psychiat Nervenkr 226:95–112
Author information
Authors and Affiliations
Additional information
Supported by the Heisenberg-grant of the Deutsche Forschungsgemeinschaft
Rights and permissions
About this article
Cite this article
Emrich, H.M., v. Zerssen, D., Kissling, W. et al. Effect of sodium valproate on mania. Arch. Psychiat. Nervenkr. 229, 1–16 (1980). https://doi.org/10.1007/BF00343800
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00343800